Ian W. Flinn, MD, PhD
Several promising combinations are being investigated for patients with chronic lymphocytic leukemia (CLL), according to Ian W. Flinn, MD, citing a number of ongoing trials presented at the 2017 ASH Annual Meeting.
on Hematologic Malignancies, Flinn, director of the Blood Cancer Research Program at Sarah Cannon Research Institute, discussed ongoing advances with emerging combination regimens in CLL.
OncLive®: What recent advances have we seen in CLL?
: There are changes in the way we are treating patients with CLL. We now have the wonderful advancement of BTK inhibitors, such as ibrutinib (Imbruvica). Patients will stay on these therapies indefinitely, which has changed the natural history of the disease. We are moving the field along and are developing combination regimens.
... to read the full story